Thus, the conjoint CEA+SLex presence in the gastric carcinoma cell line and in gastric carcinoma tissues uncovered a potential new prognostic gastric cancer biomarker that can be easily translated into a clinical setting and open the opportunity for the development of a new targeted therapy. This evidence concerns the gene CEACAM5 and gastric carcinoma.